Beam Therapeutics (BEAM) Current Leases (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Current Leases data on file, last reported at $14.8 million in Q1 2026.

• On a quarterly basis, Current Leases rose 11.89% year-over-year to $14.8 million in Q1 2026; TTM through Mar 2026 was $14.8 million, a 11.89% increase from a year earlier, with the FY2025 full-year figure at $14.4 million, up 6.64% from the prior year.
• Current Leases for Q1 2026 stood at $14.8 million, up from $14.4 million in the prior quarter.
• Over the last five years, Current Leases for BEAM reached as high as $14.8 million in Q1 2026 and fell as low as $912000.0 in Q2 2023.
• Historically, Current Leases has averaged $10.4 million across 5 years, with a median of $12.6 million in 2024.
• Across the five-year window, Current Leases sank 88.96% in 2023 and surged 1286.07% in 2024, its largest moves.
• Year by year, Current Leases stood at $10.4 million in 2022, then grew by 23.1% to $12.8 million in 2023, then gained by 5.41% to $13.5 million in 2024, then climbed by 6.64% to $14.4 million in 2025, then increased by 2.9% to $14.8 million in 2026.
• Per Business Quant data, the three most recent Current Leases figures were $14.8 million in Q1 2026, $14.4 million in Q4 2025, and $12.7 million in Q3 2025.